Health and Fitness Health and Fitness
Fri, October 28, 2011
[ Fri, Oct 28th 2011 ] - Market Wire
A Biogen Idec pozitv eredmnyt rt el a sclerosis m .. BG-12 (Dimethyl Fumarate) harmadik fzis klinikai
[ Fri, Oct 28th 2011 ] - Market Wire
MannKind Corporation to Hold 2011 Third Quarter F .. ncial Results Conference Call on November 3, 2011
[ Fri, Oct 28th 2011 ] - Market Wire
Advaxis Receives Additional Financing
[ Fri, Oct 28th 2011 ] - Market Wire
What's Ahead: Today's Economic Outlook - Equity R .. Mylan Inc. and Medicis Pharmaceutical Corporation
[ Fri, Oct 28th 2011 ] - Market Wire
The Medicines Company and Daiichi Sankyo Announce Angiox(R) (Bivalirudin) Co-Promotion for Germany
[ Fri, Oct 28th 2011 ] - Market Wire
Hansen Medical Announces Third Quarter and Nine-Month 2011 Results Conference Call
[ Fri, Oct 28th 2011 ] - Market Wire
Medtronic Named One of the aWorldas 25 Best Multinational Workplacesa
[ Fri, Oct 28th 2011 ] - Market Wire
Egan-Jones Recommends Poniard Shareholders Vote " .. osed Merger With ALLOZYNE and Reverse Stock Split
[ Fri, Oct 28th 2011 ] - Market Wire
Pfizer Completes Acquisition Of Icagen
[ Fri, Oct 28th 2011 ] - Market Wire
Analyst Research on Sequenom Inc. and Life Techno .. Companies Succeeding in Bringing Products to the
[ Fri, Oct 28th 2011 ] - Market Wire
Gilead deposita una domanda di approvazione di nu .. per gli Alimenti e i Medicinali statunitense (Foo
[ Fri, Oct 28th 2011 ] - Market Wire
Salix Pharmaceuticals Previews American College of Gastroenterology 2011
[ Fri, Oct 28th 2011 ] - Market Wire
Gilead stellt Zulassungsantrag bei der FDA fr neu .. r HIV-Therapie mit tglich einer einzigen Tablette
[ Fri, Oct 28th 2011 ] - Market Wire
Threshold Pharmaceuticals Reports Further Promising Data With TH-302 in Soft Tissue Sarcoma
Thu, October 27, 2011
[ Thu, Oct 27th 2011 ] - Market Wire
Basilea announces date and agenda of extraordinary general meeting
[ Thu, Oct 27th 2011 ] - Market Wire
Afexa Announces Additional Take-Up of Shares Unde .. eeting of Shareholders to Approve the Privatizati
[ Thu, Oct 27th 2011 ] - Market Wire
HeartWare International Announces Planned Departure of Chief Financial Officer
[ Thu, Oct 27th 2011 ] - Market Wire
HeartWare International Reports Third Quarter 201 .. #59; 54% Increase From $13.8 Million in Third
[ Thu, Oct 27th 2011 ] - Market Wire
FDA Advisory Panel Makes Recommendation on Invest .. Ablation System for Treatment of Persistent or L
[ Thu, Oct 27th 2011 ] - Market Wire
Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
[ Thu, Oct 27th 2011 ] - Market Wire
Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
[ Thu, Oct 27th 2011 ] - Market Wire
Cadence Pharmaceuticals to Host Conference Call a .. uarter 2011 Financial Results on November 3, 2011
[ Thu, Oct 27th 2011 ] - Market Wire
Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
[ Thu, Oct 27th 2011 ] - Market Wire
Repligen Acquires Business of Novozymes Biopharma Sweden AB
[ Thu, Oct 27th 2011 ] - Market Wire
Repligen Reports Second Quarter Fiscal Year 2012 Financial Results
[ Thu, Oct 27th 2011 ] - Market Wire
Glancy Binkow & Goldberg LLP Announces Investigation of HealthSpring, Inc.
[ Thu, Oct 27th 2011 ] - Market Wire
Glancy Binkow & Goldberg LLP Announces Investigation of Adolor Corporation
[ Thu, Oct 27th 2011 ] - Market Wire
Pacific Biosciences Appoints Michael W. Hunkapiller as Executive Chairman
[ Thu, Oct 27th 2011 ] - Market Wire
Gilead Submits New Drug Application to U.S. FDA for Once-Daily, Single-Tablet aQuada HIV Regimen
[ Thu, Oct 27th 2011 ] - Market Wire
Trimel Pharmaceuticals Corporation to Report Third Quarter 2011 Results and Host a Conference Call

Trimel Pharmaceuticals Corporation to Report Third Quarter 2011 Results and Host a Conference Call


Published on 2011-10-27 10:08:38 - Market Wire
  Print publication without navigation


October 27, 2011 13:00 ET

Trimel Pharmaceuticals Corporation to Report Third Quarter 2011 Results and Host a Conference Call

TORONTO, CANADA--(Marketwire - Oct. 27, 2011) - Trimel Pharmaceuticals Corporation (TSX:TRL) will report on the third quarter results for the Company and its subsidiaries for the period ended September 30, 2011 on Wednesday, November 2, 2011 after the market closes.

Management of the Company will host a conference call to discuss these results on Thursday, November 3, 2011, at 8:30 a.m. Eastern Time. Presenting from Trimel will be Bruce Brydon, Chairman of the Board and Chief Executive Officer, and Kenneth Howling, Chief Financial Officer.

To access the call live, please dial 416-340-2219 (Toronto), 1-866-226-1798 (Canada and U.S.), and 00-800-9559-6849 (International). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.

A replay of the conference call will be available until 7:00 p.m. Eastern Time on Thursday, November 10, 2011 by dialing 905-694-9451 (Toronto), 1-800-408-3053 (Canada and U.S.) or 00-800-3366-3052 (International), using access code: 4012435#.

For further information regarding Trimel Pharmaceuticals Corporation, please contact either Bruce Brydon at 416-679-0711 or Kenneth Howling at 416-679-0536 or via email at [ ir@trimelpharmaceuticals.com ].

About Trimel

Trimel Pharmaceuticals Corporation (TSX:TRL) - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT, a bio-adhesive intranasal Testosterone gel for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit [ www.trimelpharmaceuticals.com ].



Contributing Sources